[Antitumor action of Ser. marcescens nuclease covalently bound to soluble dextrans].
The antitumor effect of Ser. marcescens nuclease, modified by covalent binding using the method of diazocoupling with m-aminobenzyloxymethyl dextran of molecular weight 20 000, 40 000, 60 000, exceeds 3--4 times the antitumor effect of the native enzyme in relation to Ehrlich ascites carcinoma in contact tumor cells exposure. In intramuscular injection of the enzyme the nuclease preparation modified by dextran of molecular weight 40 000 showed the greatest antitumor activity against Ehrlich carcinoma and sarcoma 37.
D000818:Animals; D000970:Antineoplastic Agents; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D003911:Dextrans / Q000494:pharmacology* / Q000627:therapeutic use; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D004720:Endonucleases / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D011485:Protein Binding; D012511:Sarcoma 37 / Q000188:drug therapy; D012706:Serratia marcescens / Q000201:enzymology*; D012995:Solubility
D000970:Antineoplastic Agents; D003911:Dextrans; D004338:Drug Combinations; D004720:Endonucleases
Protivoopukholevoe deĭstvie nukleazy Ser. marcescens, kovalentno sviazannoĭ s rastvorimymi dekstranami.